Steven Leming
About Steven Leming
Steven Leming is the Senior Manager of US Cell Therapy Finance at Bristol Myers Squibb, with a background in accounting and audit from previous roles at The Siegfried Group, SiriusXM, and KPMG US.
Company
Steven Leming is currently employed at Bristol Myers Squibb in Summit, New Jersey, United States. He holds the position of Senior Manager, US Cell Therapy Finance. He joined the company in October 2021 and has been focusing on the financial aspects of cell therapy in the U.S. market.
Title
Steven Leming serves as the Senior Manager of US Cell Therapy Finance at Bristol Myers Squibb. His role involves overseeing the financial strategies and operations pertaining to cell therapy within the U.S. market.
Work Experience
Steven Leming has a comprehensive background in finance and accounting. Before joining Bristol Myers Squibb, he worked at The Siegfried Group as a Manager in New Jersey for 8 months in 2021 and as an Associate Manager from 2019 to 2020 in the New York Metro area. He also held a senior accounting role at SiriusXM in New York City from 2017 to 2019. Additionally, he has significant experience in audit, having worked at KPMG US from 2013 to 2017, first as an intern and later progressing to the position of Senior Audit Associate in Short Hills, NJ.
Education and Expertise
Steven Leming holds a Bachelor of Science (B.S.) degree in Accountancy from The College of New Jersey, where he studied from 2010 to 2014. He also attended Hamilton High School West from 2006 to 2010. His academic background in accounting has provided him with a solid foundation for his roles in finance and audit.
Background
Steven Leming has accumulated extensive experience in the finance and auditing sectors. Starting his career with an internship at KPMG US, he progressed through various roles, enhancing his expertise in both New Jersey and New York Metro areas. His professional journey includes significant roles at SiriusXM and The Siegfried Group before his current position at Bristol Myers Squibb. His career trajectory reflects a strong commitment to the fields of finance and cellular therapy.